NO318984B1 - Farmasoytisk preparat omfattende et lite opploslig salt av en LHRH analog samt anvendelse av et lite opploslig salt av en LHRH analog - Google Patents

Farmasoytisk preparat omfattende et lite opploslig salt av en LHRH analog samt anvendelse av et lite opploslig salt av en LHRH analog Download PDF

Info

Publication number: NO318984B1
Authority: NO; Norway
Prior art keywords: salt; lhrh analogue; soluble salt; cetrorelix; preparation according
Prior art date: 1993-12-09

Application number

NO19961877A

Other languages

English (en)

Norwegian (no)

Other versions

NO961877L (no

NO961877D0 (no

Inventor

Juergen Engel

Peter Hilgard

Karin Klokkersbethke

Thomas Reissman

Original Assignee

Zentaris Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-09

Filing date

1996-05-09

Publication date

2005-05-30

1996-05-09 Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh

1996-05-09 Publication of NO961877L publication Critical patent/NO961877L/no

1996-05-09 Publication of NO961877D0 publication Critical patent/NO961877D0/no

1996-06-10 Priority claimed from US08/661,017 external-priority patent/US5773032A/en

2005-05-30 Publication of NO318984B1 publication Critical patent/NO318984B1/no

Links

150000003839 salts Chemical class 0.000 title claims abstract description 28
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 title claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 title description 2
239000002245 particle Substances 0.000 claims description 20
108700008462 cetrorelix Proteins 0.000 claims description 18
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical group C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 16
206010028980 Neoplasm Diseases 0.000 claims description 12
229960003230 cetrorelix Drugs 0.000 claims description 12
239000007924 injection Substances 0.000 claims description 9
238000002347 injection Methods 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 9
239000000725 suspension Substances 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 7
229920002988 biodegradable polymer Polymers 0.000 claims description 6
239000004621 biodegradable polymer Substances 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims description 5
239000003163 gonadal steroid hormone Substances 0.000 claims description 5
NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 4
108010070670 antarelix Proteins 0.000 claims description 4
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical group C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 4
108700032141 ganirelix Proteins 0.000 claims description 4
229960003794 ganirelix Drugs 0.000 claims description 4
201000009273 Endometriosis Diseases 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 3
239000002790 bombesin antagonist Substances 0.000 claims description 2
239000003925 fat Substances 0.000 claims 2
229940123804 Bombesin antagonist Drugs 0.000 claims 1
230000005923 long-lasting effect Effects 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 13
239000012730 sustained-release form Substances 0.000 abstract description 13
UCANQOXFIYWYIX-IDEADWEOSA-N (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid Chemical compound OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O.CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O.CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O UCANQOXFIYWYIX-IDEADWEOSA-N 0.000 abstract description 10
238000013268 sustained release Methods 0.000 abstract description 9
108090000765 processed proteins & peptides Proteins 0.000 description 25
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 24
239000000203 mixture Substances 0.000 description 20
KFEFLCOCAHJBEA-ANRVCLKPSA-N cetrorelix acetate Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KFEFLCOCAHJBEA-ANRVCLKPSA-N 0.000 description 17
238000000034 method Methods 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
238000009472 formulation Methods 0.000 description 14
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 13
239000013543 active substance Substances 0.000 description 13
229940079593 drug Drugs 0.000 description 13
239000003814 drug Substances 0.000 description 13
239000002244 precipitate Substances 0.000 description 12
239000000243 solution Substances 0.000 description 12
229960003604 testosterone Drugs 0.000 description 12
230000008569 process Effects 0.000 description 8
229960001865 cetrorelix acetate Drugs 0.000 description 7
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 7
229950005627 embonate Drugs 0.000 description 7
239000004310 lactic acid Substances 0.000 description 7
235000014655 lactic acid Nutrition 0.000 description 7
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 7
108010037003 Buserelin Proteins 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
108010069236 Goserelin Proteins 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
229920001577 copolymer Polymers 0.000 description 6
230000001629 suppression Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
108010000817 Leuprolide Proteins 0.000 description 4
241000700159 Rattus Species 0.000 description 4
108010050144 Triptorelin Pamoate Proteins 0.000 description 4
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 4
230000002354 daily effect Effects 0.000 description 4
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
229960002913 goserelin Drugs 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000013557 residual solvent Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
230000002483 superagonistic effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 3
102100024028 Progonadoliberin-1 Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229960002719 buserelin Drugs 0.000 description 3
230000000711 cancerogenic effect Effects 0.000 description 3
231100000315 carcinogenic Toxicity 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
229960004338 leuprorelin Drugs 0.000 description 3
239000007923 nasal drop Substances 0.000 description 3
229940100662 nasal drops Drugs 0.000 description 3
-1 poly(lactic acid-glycolic acid) copolymer Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000000126 substance Substances 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 2
239000005639 Lauric acid Substances 0.000 description 2
229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 2
108010021717 Nafarelin Proteins 0.000 description 2
239000000556 agonist Substances 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
229960005064 buserelin acetate Drugs 0.000 description 2
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
229920006237 degradable polymer Polymers 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000003581 hormone blood level Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 2
229960004309 nafarelin acetate Drugs 0.000 description 2
238000002559 palpation Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229960004824 triptorelin Drugs 0.000 description 2
238000001291 vacuum drying Methods 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
AYRABHFHMLXKBT-UHFFFAOYSA-N 2,6-Dimethyl-anthracen Natural products C1=C(C)C=CC2=CC3=CC(C)=CC=C3C=C21 AYRABHFHMLXKBT-UHFFFAOYSA-N 0.000 description 1
ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
BPQZYOJIXDMZSX-UHFFFAOYSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 BPQZYOJIXDMZSX-UHFFFAOYSA-N 0.000 description 1
VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010018852 Haematoma Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
102100022831 Somatoliberin Human genes 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
159000000021 acetate salts Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000006053 animal diet Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000036576 dermal application Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000002474 gonadorelin antagonist Substances 0.000 description 1
229960003690 goserelin acetate Drugs 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 description 1
108010083551 iturelix Proteins 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
229960000907 methylthioninium chloride Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
150000002942 palmitic acid derivatives Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
238000012805 post-processing Methods 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
229960000611 pyrimethamine Drugs 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000007790 scraping Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A61K38/105—Bombesin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19961877A 1993-12-09 1996-05-09 Farmasoytisk preparat omfattende et lite opploslig salt av en LHRH analog samt anvendelse av et lite opploslig salt av en LHRH analog NO318984B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE4342092A DE4342092B4 (de)	1993-12-09	1993-12-09	Langwirkende Injektionssuspension und Verfahren zur Herstellung
PCT/EP1994/003904 WO1995015767A1 (en)	1993-12-09	1994-11-25	Long-acting injection suspensions and a process for their preparation
US08/661,017 US5773032A (en)	1993-12-09	1996-06-10	Long-acting injection suspensions and a process for their preparation

Publications (3)

Publication Number	Publication Date
NO961877L NO961877L (no)	1996-05-09
NO961877D0 NO961877D0 (no)	1996-05-09
NO318984B1 true NO318984B1 (no)	2005-05-30

Family

ID=25931926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19961877A NO318984B1 (no)	1993-12-09	1996-05-09	Farmasoytisk preparat omfattende et lite opploslig salt av en LHRH analog samt anvendelse av et lite opploslig salt av en LHRH analog

Country Status (27)

Country	Link
EP (1)	EP0732934B1 (pl)
JP (1)	JPH09509145A (pl)
CN (2)	CN1248732C (pl)
AT (1)	ATE310530T1 (pl)
AU (1)	AU677748B2 (pl)
BR (1)	BR9408272A (pl)
CZ (1)	CZ291025B6 (pl)
DE (1)	DE4342092B4 (pl)
DK (1)	DK0732934T3 (pl)
EE (1)	EE03224B1 (pl)
EG (1)	EG20787A (pl)
ES (1)	ES2251715T3 (pl)
FI (1)	FI116121B (pl)
HK (1)	HK1063746A1 (pl)
HR (1)	HRP940978B1 (pl)
HU (1)	HU217081B (pl)
IL (1)	IL111928A (pl)
LV (1)	LV11596B (pl)
NO (1)	NO318984B1 (pl)
NZ (1)	NZ277239A (pl)
PL (1)	PL186929B1 (pl)
RO (1)	RO119343B1 (pl)
RS (1)	RS49511B (pl)
RU (1)	RU2152222C1 (pl)
SK (2)	SK284981B6 (pl)
WO (1)	WO1995015767A1 (pl)
ZA (1)	ZA949798B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6828415B2 (en) *	1993-02-19	2004-12-07	Zentaris Gmbh	Oligopeptide lyophilisate, their preparation and use
DE69434553T2 (de) *	1993-12-09	2006-08-10	Zentaris Gmbh	Lang wirkende injektionssuspensionen von lhrh-analogen und ein verfahren für ihre herstellung
WO1998032423A1 (en) *	1997-01-29	1998-07-30	Takeda Chemical Industries, Ltd.	Sustained-release microspheres, their production and use
DE10040700A1 (de) *	2000-08-17	2002-02-28	Asta Medica Ag	Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
WO2002047722A1 (fr) *	2000-12-15	2002-06-20	Takeda Chemical Industries, Ltd.	Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
TWI332407B (en) *	2001-06-29	2010-11-01	Takeda Chemical Industries Ltd	Controlled release composition and method of producting the same
US7098305B2 (en) *	2001-09-06	2006-08-29	Ardana Bioscience Limited	Sustained release of microcrystalline peptide suspensions
EP1674082A1 (de)	2004-12-22	2006-06-28	Zentaris GmbH	Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
BRPI0720582B1 (pt)	2006-12-18	2021-08-24	Takeda Pharmaceutical Company Limited	Composição de liberação prolongada, processo para a preparação da mesma, composição farmacêutica, agente profilático ou terapêutico, e, uso de uma substância fisiologicamente ativa
RU2548753C2 (ru) *	2009-11-16	2015-04-20	Ипсен Фарма С.А.С.	Фармацевтические композиции лигандов рецепторов меланокортинов
CN102504018A (zh) *	2011-10-28	2012-06-20	沈阳药科大学	可持续释放的蜂毒肽帕莫酸盐及其制剂
WO2017167180A1 (zh) *	2016-03-29	2017-10-05	上海华汇拓医药科技有限公司	沃替西汀的帕莫酸盐及其晶型
CN108969478A (zh) *	2018-08-29	2018-12-11	江南大学	一种美金刚难溶盐缓释注射剂及其制备方法
CN110003195B (zh) *	2019-05-21	2020-05-26	湖北中医药大学	鲁拉西酮晶体及其制备方法和在注射给药***中的应用
CN112569340A (zh) *	2020-12-31	2021-03-30	苏州素仕生物科技有限公司	一种无菌布舍瑞林注射液及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3852422A (en) *	1971-06-26	1974-12-03	Serono Ist Farm	Long-active gonadotropins
NZ181036A (en) *	1975-06-12	1978-12-18	A Schally	Luteinising hormone releasing hormone analogues and intermediates therefor
GB2209937B (en) *	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
FR2647677B1 (fr) *	1989-05-31	1991-09-27	Roussel Uclaf	Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
CH679207A5 (pl) *	1989-07-28	1992-01-15	Debiopharm Sa
CH683149A5 (fr) *	1991-07-22	1994-01-31	Debio Rech Pharma Sa	Procédé pour la préparation de microsphères en matériau polymère biodégradable.

1993
- 1993-12-09 DE DE4342092A patent/DE4342092B4/de not_active Expired - Fee Related
1994
- 1994-11-25 RU RU96115021/14A patent/RU2152222C1/ru not_active IP Right Cessation
- 1994-11-25 WO PCT/EP1994/003904 patent/WO1995015767A1/en active IP Right Grant
- 1994-11-25 NZ NZ277239A patent/NZ277239A/en not_active IP Right Cessation
- 1994-11-25 CN CNB021593949A patent/CN1248732C/zh not_active Expired - Fee Related
- 1994-11-25 DK DK95903282T patent/DK0732934T3/da active
- 1994-11-25 SK SK5090-2005A patent/SK284981B6/sk not_active IP Right Cessation
- 1994-11-25 CZ CZ19961420A patent/CZ291025B6/cs not_active IP Right Cessation
- 1994-11-25 RO RO96-01143A patent/RO119343B1/ro unknown
- 1994-11-25 HU HU9601584A patent/HU217081B/hu not_active IP Right Cessation
- 1994-11-25 BR BR9408272A patent/BR9408272A/pt not_active Application Discontinuation
- 1994-11-25 EE EE9600061A patent/EE03224B1/xx not_active IP Right Cessation
- 1994-11-25 JP JP7515921A patent/JPH09509145A/ja not_active Ceased
- 1994-11-25 CN CNB941944050A patent/CN1136916C/zh not_active Expired - Fee Related
- 1994-11-25 EP EP95903282A patent/EP0732934B1/en not_active Expired - Lifetime
- 1994-11-25 ES ES95903282T patent/ES2251715T3/es not_active Expired - Lifetime
- 1994-11-25 AU AU12199/95A patent/AU677748B2/en not_active Ceased
- 1994-11-25 SK SK667-96A patent/SK284980B6/sk not_active IP Right Cessation
- 1994-11-25 AT AT95903282T patent/ATE310530T1/de not_active IP Right Cessation
- 1994-11-25 PL PL94314913A patent/PL186929B1/pl not_active IP Right Cessation
- 1994-12-07 EG EG77194A patent/EG20787A/xx active
- 1994-12-08 IL IL11192894A patent/IL111928A/xx not_active IP Right Cessation
- 1994-12-08 RS YU72194A patent/RS49511B/sr unknown
- 1994-12-08 ZA ZA949798A patent/ZA949798B/xx unknown
- 1994-12-08 HR HR940978A patent/HRP940978B1/xx not_active IP Right Cessation
1996
- 1996-05-09 NO NO19961877A patent/NO318984B1/no not_active IP Right Cessation
- 1996-06-06 FI FI962354A patent/FI116121B/fi not_active IP Right Cessation
- 1996-07-09 LV LVP-96-226A patent/LV11596B/en unknown
2004
- 2004-09-07 HK HK04106711A patent/HK1063746A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
EG20787A (en)	2000-02-29
CN1248732C (zh)	2006-04-05
WO1995015767A1 (en)	1995-06-15
DE4342092B4 (de)	2007-01-11
EE03224B1 (et)	1999-10-15
EP0732934B1 (en)	2005-11-23
CN1136779A (zh)	1996-11-27
RS49511B (sr)	2006-10-27
RO119343B1 (ro)	2004-08-30
FI116121B (fi)	2005-09-30
FI962354A (fi)	1996-06-06
NZ277239A (en)	1997-03-24
CN1136916C (zh)	2004-02-04
AU1219995A (en)	1995-06-27
SK66796A3 (en)	1997-08-06
AU677748B2 (en)	1997-05-01
HU9601584D0 (en)	1996-08-28
BR9408272A (pt)	1996-12-17
HK1063746A1 (en)	2005-01-14
NO961877L (no)	1996-05-09
EP0732934A1 (en)	1996-09-25
FI962354A0 (fi)	1996-06-06
SK284980B6 (sk)	2006-03-02
PL186929B1 (pl)	2004-04-30
CN1494919A (zh)	2004-05-12
CZ142096A3 (en)	1996-12-11
DK0732934T3 (da)	2006-03-27
RU2152222C1 (ru)	2000-07-10
ATE310530T1 (de)	2005-12-15
YU72194A (sh)	1997-03-07
NO961877D0 (no)	1996-05-09
HRP940978A2 (en)	1997-02-28
JPH09509145A (ja)	1997-09-16
IL111928A0 (en)	1995-03-15
LV11596A (lv)	1996-12-20
HU217081B (hu)	1999-11-29
HUT75712A (en)	1997-05-28
CZ291025B6 (cs)	2002-12-11
DE4342092A1 (de)	1995-06-14
ZA949798B (en)	1995-08-18
IL111928A (en)	1999-11-30
SK284981B6 (sk)	2006-03-02
HRP940978B1 (en)	2006-08-31
LV11596B (en)	1997-06-20
ES2251715T3 (es)	2006-05-01
PL314913A1 (en)	1996-09-30

Legal Events

Date	Code	Title	Description
2011-06-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US5773032A (en)	1998-06-30	Long-acting injection suspensions and a process for their preparation
EP0732934B1 (en)	2005-11-23	Long-acting injection suspensions of an lhrh analogue and a process for their preparation
EP1011648B1 (en)	2001-11-07	Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
EP1404357B1 (en)	2009-12-23	Gonadotropin releasing hormone antagonist in gel-forming concentrations
EP3576771B1 (en)	2022-03-09	Compositions and methods for long term release of ganadotropin-releasing hormone (gnrh) antagonists
AU701837B2 (en)	1999-02-04	Novel formulation for peptide release
KR20190036449A (ko)	2019-04-04	지속형 팔미트산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물
US20050019367A1 (en)	2005-01-27	Biodegradable implant comprising a polylactide polymer and a lh-rh analogue
KR100344330B1 (ko)	2002-11-30	지속성주사현탁제
TWI376241B (en)	2012-11-11	Pharmaceutical compositions with enhanced stability
MXPA00001592A (en)	2001-03-05	Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer